Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMN1S35)

Drug Name
5,6-dichloro-3,4-dihydroquinazolin-2-amine Drug Info
Synonyms
Anagrelide impurity 5; 2-Amino-5,6-dichloro-3,4-dihydroquinazoline; 444904-63-6; CHEMBL1548; 2-Quinazolinamine, 5,6-dichloro-1,4-dihydro-; W-202785; SCHEMBL1569300; CTK1D2410; DTXSID80432648; VBKOTIVQMCTTAQ-UHFFFAOYSA-N; ZINC29130869; BDBM50371434; AKOS030254941; 5,6-Dichloro-1,4-dihydro-2-quinazolinamine; 2-amino-5,6-dichloro-3,4dihydroquinazoline; FT-0722369
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
9904281
CAS Number
CAS 444904-63-6
TTD Drug ID
DMN1S35

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Discontinued Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting 5-HT 1D receptor (HTR1D)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [2]
Eletriptan DMW649X Migraine 8A80 Approved [3]
Zolmitriptan DM1IB4Q Migraine 8A80 Approved [3]
Frovatriptan DM7RE8P Migraine 8A80 Approved [3]
Sumatriptan DMVYXR8 Cluster headache 8A81.0 Approved [4]
Rizatriptan DMDJMA3 Migraine 8A80 Approved [5]
Almogran DM7I64Z Migraine 8A80 Approved [6]
Neu-P11 DMIQDFW Alzheimer disease 8A20 Phase 2 [7]
FKB01MD DM2O7NM N. A. N. A. Phase 2 [8]
NXN-188 DMMBAIH Migraine 8A80 Phase 2 [9]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 5A receptor (HTR5A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [10]
(+/-)-nantenine DM0L3GE Discovery agent N.A. Investigative [11]
SEROTONIN DMOFCRY Discovery agent N.A. Investigative [12]
5-CT DM260KD Discovery agent N.A. Investigative [13]
TFMPP DMAC8TP Discovery agent N.A. Investigative [14]
MPDT DMYX31S Discovery agent N.A. Investigative [15]
5-chloro-3,4-dihydroquinazolin-2-amine DMKEFJ0 Discovery agent N.A. Investigative [1]
EDMT DMS3AXK Discovery agent N.A. Investigative [15]
5-chloro-4-methyl-3,4-dihydroquinazolin-2-amine DM7FZU2 Discovery agent N.A. Investigative [1]
[3H]5-CT DMEAHFZ Discovery agent N.A. Investigative [16]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 6 receptor (HTR6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LU AE58054 DMWGRQD Schizophrenia 6A20 Phase 3 [17]
SB-742457 DM6L4ZT Alzheimer disease 8A20 Phase 3 [18]
AVN 211 DMVB4OS Schizophrenia 6A20 Phase 2/3 [19]
SYN120 DMDF7XB Parkinson disease 8A00.0 Phase 2 [20]
AVN 101 DMJFLBC Alzheimer disease 8A20 Phase 2 [19]
SYN-120 DMPW0UL Alzheimer disease 8A20 Phase 2 [21]
PF-05212377 DMPVQYR Alzheimer disease 8A20 Phase 2 [22]
AVN 322 DMK2LGM Cognitive impairment 6D71 Phase 2 [18]
SAM-531 DMHVJZ6 Alzheimer disease 8A20 Phase 2 [23]
SUVN-502 DMQD753 Alzheimer disease 8A20 Phase 2 [24]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 2A receptor (HTR2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [25]
ZOTEPINE DMF3VXA Anxiety disorder 6B00-6B0Z Approved [26]
Iloperidone DM6AUFY Schizophrenia 6A20 Approved [27]
Flibanserin DM70DTN Depression 6A70-6A7Z Approved [28]
Lurasidone hydrochloride DMCVPXO Schizophrenia 6A20 Approved [29]
Aniracetam DMOIFW0 Cerebrovascular ischaemia 8B1Z Approved [30]
lumateperone tosylate DMQ8HOJ Schizophrenia 6A20 Approved [31]
Sarpogrelate DMGLP6S Diabetic complication 5A2Y Approved [32]
Pimavanserin DMR7IVC Parkinson disease 8A00.0 Approved [33]
Zicronapine DMP8ESD Schizophrenia 6A20 Phase 3 [34]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 3A receptor (HTR3A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dolasetron DMMG26Z Nausea MD90 Approved [35]
Alosetron DML2A03 Diarrhea-predominant irritable bowel syndrome DD91.01 Approved [36]
Tropisetron DMNSJ7V Fibromyalgia MG30.01 Approved [37]
Palonosetron DMBHMOX Nausea MD90 Approved [38]
Levetiracetam DMTGDN8 Epilepsy 8A60-8A68 Approved [37]
Procaine DM4LSNE Anaesthesia 9A78.6 Approved [39]
Cilansetron DMP0NGX Irritable bowel syndrome DD91.0 Phase 3 [40]
BEMESETRON DMSPJX9 N. A. N. A. Discontinued in Phase 3 [41]
Norcisapride DMJSKUI Gastroesophageal reflux disease DA22.Z Discontinued in Phase 2 [42]
YM-114 DML2IXO Nausea MD90 Discontinued in Phase 2 [43]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 1A receptor (HTR1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Trazodone DMK1GBJ Depression 6A70-6A7Z Approved [3]
Buspirone DMBS632 Anxiety disorder 6B00-6B0Z Approved [44]
OPC-34712 DMHG57U Major depressive disorder 6A70.3 Approved [45]
Vilazodone DM4LECQ Major depressive disorder 6A70.3 Approved [46]
Flibanserin DM70DTN Depression 6A70-6A7Z Approved [28]
Gepirone DMGX5Q0 Major depressive disorder 6A70.3 Approved [47]
TERTATOLOL DM2L3D5 Hypertension BA00-BA04 Approved [48]
Urapidil DMD59GI Hypertension BA00-BA04 Approved [49]
Treximet DMU54QB Migraine 8A80 Approved [50]
CM-2395 DMASPWR Schizophrenia 6A20 Phase 3 [51]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 7 receptor (HTR7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
RP5063 DMKUE8O Schizophrenia 6A20 Phase 2 [8]
JNJ-18038683 DMV1T59 Major depressive disorder 6A70.3 Phase 2 [52]
AVN-101 DMOGFNI Cognitive impairment 6D71 Phase 2 [53]
ATI-9242 DM6GKMU Schizophrenia 6A20 Phase 1 [54]
PMID30124346-Compound-34TABLE4 DM2G3VE Attention deficit hyperactivity disorder 6A05.Z Patented [55]
PMID30124346-Compound-13TABLE4 DMHTJVA Attention deficit hyperactivity disorder 6A05.Z Patented [55]
Carbamide derivative 2 DMW5GI3 N. A. N. A. Patented [56]
4-oxadiazole derivative 1 DMWFHKR N. A. N. A. Patented [56]
SB-269970 DM8WTGA Sleep-wake disorder 7A00-7B2Z Terminated [57]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G Discovery agent N.A. Investigative [58]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 2C receptor (HTR2C)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [25]
Lorcaserin DMG6OYJ Obesity 5B81 Approved [59]
Tramadol DMRQD04 Osteoarthritis FA00-FA05 Approved [60]
Mirtazapine DML53ZJ Depression 6A70-6A7Z Approved [61]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [62]
Methysergide DM1EF73 Migraine 8A80 Approved [63]
Eltoprazine DMW6C81 Attention deficit hyperactivity disorder 6A05.Z Phase 3 [64]
M100907 DM7ZFBA Sleep-wake disorder 7A00-7B2Z Phase 3 [65]
SR46349B DM1ODMR Primary insomnia 7A00 Phase 3 [66]
Vabicaserin DM9GZW6 Psychotic disorder 6A20-6A25 Phase 2 [67]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1A receptor (HTR1A) TTSQIFT 5HT1A_HUMAN Inhibitor [1]
5-HT 1D receptor (HTR1D) TT6MSOK 5HT1D_HUMAN Inhibitor [1]
5-HT 2A receptor (HTR2A) TTJQOD7 5HT2A_HUMAN Inhibitor [1]
5-HT 2C receptor (HTR2C) TTWJBZ5 5HT2C_HUMAN Inhibitor [1]
5-HT 3A receptor (HTR3A) TTPC4TU 5HT3A_HUMAN Inhibitor [1]
5-HT 5A receptor (HTR5A) TTRUFDT 5HT5A_HUMAN Inhibitor [1]
5-HT 6 receptor (HTR6) TTJS8PY 5HT6R_HUMAN Inhibitor [1]
5-HT 7 receptor (HTR7) TTO9X1H 5HT7R_HUMAN Inhibitor [1]

References

1 Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
2 Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
5 An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210.
6 Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75.
7 Clinical pipeline report, company report or official report of Neurim Pharmaceuticals.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Company report (NeurAxon)
10 Cloning and characterisation of the human 5-HT5A serotonin receptor. FEBS Lett. 1994 Dec 5;355(3):242-6.
11 Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
12 Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
13 Expression of functional mouse 5-HT5A serotonin receptor in the methylotrophic yeast Pichia pastoris: pharmacological characterization and localization. FEBS Lett. 1995 Dec 27;377(3):451-6.
14 Mouse 5-hydroxytryptamine5A and 5-hydroxytryptamine5B receptors define a new family of serotonin receptors: cloning, functional expression, and chromosomal localization. Mol Pharmacol. 1993 Mar;43(3):313-9.
15 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8.
16 Human 5-HT(5) receptors: the 5-HT(5A) receptor is functional but the 5-HT(5B) receptor was lost during mammalian evolution. Eur J Pharmacol. 2001 Apr 27;418(3):157-67.
17 Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33.
18 5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013; 5(2): 15.
19 Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010 January; 11(1): 80-91.
20 Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018 Nov;17(11):804-822.
21 The Serotonin-6 Receptor as a Novel Therapeutic Target. Exp Neurobiol. 2011 December; 20(4): 159-168.
22 PF-05212377 Alzheimer's Disease (Phase 2). Pfizer.
23 Activation of 5-HT6 receptors modulates sleep-wake activity and hippocampal theta oscillation. ACS Chem Neurosci. 2013 Jan 16;4(1):191-9.
24 Novel and Potent 5-Piperazinyl Methyl-N1-aryl Sulfonyl Indole Derivatives as 5-HT6 Receptor Ligands. ACS Med Chem Lett. 2010 October 14; 1(7): 340-344.
25 Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
26 Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
27 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
28 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
29 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
30 Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
31 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
32 Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
33 Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
34 Clinical pipeline report, company report or official report of Lundbeck.
35 Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, do... Lancet Oncol. 2009 Feb;10(2):115-24.
36 Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009 Jul;104(7):1831-43; quiz 1844.
37 Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62.
38 Management of postoperative nausea and vomiting: focus on palonosetron. Ther Clin Risk Manag. 2009 Feb;5(1):21-34.
39 Local anesthetics have different mechanisms and sites of action at recombinant 5-HT3 receptors. Reg Anesth Pain Med. 2007 Nov-Dec;32(6):462-70.
40 Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.Expert Opin Investig Drugs.2005 Feb;14(2):185-93.
41 Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships. J Med Chem. 1992 Jan 24;35(2):310-9.
42 mu-Opioid/5-HT4 dual pharmacologically active agents-efforts towards an effective opioid analgesic with less GI and respiratory side effects (Part I). Bioorg Med Chem Lett. 2009 Oct 1;19(19):5679-83.
43 Effect of serotonin (5-HT)3-receptor antagonists YM060, YM114 (KAE-393), ondansetron and granisetron on 5-HT4 receptors and gastric emptying in rodents. Jpn J Pharmacol. 1995 Nov;69(3):205-14.
44 Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
45 Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
46 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
47 Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
48 Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
49 Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
50 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
51 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
52 Selective pharmacological blockade of the 5-HT7 receptor attenuates light and 8-OH-DPAT induced phase shifts of mouse circadian wheel running activity. Front Behav Neurosci. 2015 Jan 15;8:453.
53 AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders. J Alzheimers Dis. 2016 May 25;53(2):583-620.
54 Pharmacological characteristics of ATI-9242, a Novel Atypical Antipsychotic. FASEB J, April, 2010, 24(Meeting Abstract Supplement),773.12.
55 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
56 Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
57 [(3)H]-SB-269970--A selective antagonist radioligand for 5-HT(7) receptors. Br J Pharmacol. 2000 May;130(2):409-17.
58 Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
59 Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
60 The inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in Xenopus oocytes. Anesth Analg. 2004 May;98(5):1401-6, table of contents.
61 Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57.
62 Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60.
63 Spinal serotonin receptor activation modulates the exercise ventilatory response with increased dead space in goats. Respir Physiol Neurobiol. 2008 May 31;161(3):230-8.
64 Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
65 Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12.
66 SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 2002 Sep;27(3):430-41.
67 Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.